• 

  Professor Mirim Jin of Gachon University College of Medicine was invited as a speaker to the 2024 Biomolecular Horizons Congress

  September 27, 2024

  Professor Mirim Jin of Gachon University College of Medicine delivered a lecture on the topic "Highly secreted tryptophanyl-tRNA synthetase as a theranostic target for hypercytokinemic severe sepsis" at the 2024 Biomolecular Horizons Congress.The BMH 2024 Congress was held from September 22 to 26 in Melbourne, Australia, where experts gathered to discuss the latest trends in biomolecular rese...

  READ MORE >
• 

  PCMO and MirimGENE begin development of ‘WARS1’ targeted Tuberculosis treatment

  July 17, 2024

  PCMO (Public CDMO for Microbial-based Vaccines, Director Min Cho) and MirimGENE Co., Ltd. (CEO Mirim Jin) are co-developing a ' Recombinant protein therapy for Tuberculosis' based on the innovative drug platform targeting WARS1(Tryptophanyl- tRNA synthetase 1) and announced this on July 16.   source: https://www.yakup.com/news/index.html?mode=view&pmode=&cat=&cat2=&...

  READ MORE >
• 

  Professor Mirim Jin of Gachon University College of Medicine won the 34th Science and Technology Outstanding Paper Award in 2024

  July 16, 2024

  가천대 의과대학 진미림 교수가 제2회 세계 한인 과학기술인 대회에서 한국과학기술단체총연합회가 수여하는 보건의료분야 과학기술 우수논문상을 수상했다.  진미림 교수는 한국응용약물학회에서 발간하는 Biomolecules & Therapeutics 저널에 게재한 “Phytochemicals That Act on Synaptic Plasticit...

  READ MORE >
• 

  “㈜미림진, ㈜보령과 혁신신약 개발분야 업무 협약(MOU) 체결” / MirimGENE and BORYUNG signed an MOU in the field for innovative new drug development

  March 13, 2024

  ㈜미림진(대표 진미림)은 ㈜보령(대표 장두현)과 혁신신약 개발 분야 업무제휴 협약(MOU)을 체결했다고 13일 밝혔다.   ㈜미림진과 ㈜보령은 이번 전략적 업무 제휴를 바탕으로 난치성 면역 질환 혁신 신약과 제약산업 경쟁력 강화를 위해 양사의 협력을 도모할 예정이다.    &...

  READ MORE >
• 

  미림진, 패혈증 테라노스틱스 연구결과 글로벌 학술지 게재 / MirimGENE, Sepsis Theranostics research results published in global academic journals

  December 18, 2023

  We expect to present an innovative alternative that can increase the survival rate of septic shock.” Mirim Jin (CEO MirimGENE) announced on the 18th that the results of sepsis theranostics targeting WARS1 were published in the world-renowned medical journal 'EMBO Molecular Medicine (IF=14.005)' (title: 'Highly secreted tryptophanyl-tRNA synthetase as...

  READ MORE >